Biotricity Predicted To Achieve 44% Annual Growth Despite Market Risks, Analyst Says
Portfolio Pulse from Nabaparna Bhattacharya
H.C. Wainwright analyst Kevin Dede reiterated a Buy rating on Biotricity, Inc. (NASDAQ:BTCY), raising the price target to $4 from $2. The analyst acknowledged Biotricity's sales and targeted margin growth, AI tech infusion, and the opportunity to bring its platform solution to associated cardiac-related diseases. For FY24, the analyst's sales estimate stands at $13.8 million, representing an expected 44% annual growth. However, an investment in Biotricity is subject to risks like dilution, end-market product acceptance and pricing, and competition.
July 05, 2023 | 6:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biotricity, Inc. (NASDAQ:BTCY) has been given a Buy rating and a raised price target of $4 by H.C. Wainwright analyst Kevin Dede. The analyst expects a 44% annual growth in sales for FY24. However, the stock is subject to risks like dilution, end-market product acceptance and pricing, and competition.
The positive rating and raised price target by the analyst indicates a positive outlook for Biotricity, Inc. The expected 44% annual growth in sales for FY24 also suggests potential growth for the company. However, the stock is subject to various risks, which could potentially impact its performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100